Vet Med offers clinical trial for cats with history of arterial thromboembolism

March 2, 2016

Print
Writer:
Tara Bracken

Tara Bracken

Science writer, graduate student

Recent and archived articles by Tara Bracken


College of Veterinary Medicine

Contact:
Kat Yancey Gilmore

Kat Gilmore

Director of Public Relations


College of Veterinary Medicine
Work: 706-583-5485
Cell: 706-206-4526
Email:
Benjamin Brainard

Benjamin Brainard

Associate Professor of Emergency & Critical Care

Small Animal Medicine and Surgery
College of Veterinary MedicineSmall Animal Medicine and Surgery, Department of
Work: 706-542-6386
Email:

Related Sites

Athens, Ga. - Researchers at the University of Georgia Veterinary Teaching Hospital are seeking participants for a new multicenter randomized clinical trial. The three-year study dubbed "SUPER-CAT" for "study of the utility of rivaroxaban or clopidogrel for prevention of recurrent arterial thromboembolism in cats" aims to prolong life expectancy and improve quality of life in cats diagnosed with recurrent arterial thromboembolism ("saddle thrombus") through anticoagulant treatment.

Qualified participants include cats with heart disease that have survived an arterial thromboembolism.

Arterial thromboembolism, or ATE, is a serious, life-threatening condition in which a blood clot becomes lodged in the aorta or other major arteries. Though ATE is a common complication of heart disease in cats, there is no way to predict which cats will develop ATE. Few treatment options exist for cats that develop the condition, and of those that survive the episode, the median life expectancy is approximately four months without therapy.

A new therapeutic option to treat or prevent this life-threatening condition is critically needed but currently elusive.

A previous study (the FATCAT trial, for which a summary of findings can be found at www.vet.cornell.edu/news/FatCatStudy.cfm) found that treating cats with clopidogrel, a drug that blocks the pro-thrombotic activity of platelets, delayed the recurrence of ATE up to eight months longer than aspirin. The SUPER-CAT study builds on the previous study by comparing the effectiveness of clopidogrel treatment to that with rivaroxaban, a novel anticoagulant that directly inhibits Coagulation Factor Xa.

The goal of SUPER-CAT is to further extend life expectancy and improve quality of life for cats following an ATE by preventing recurrence.

Cats diagnosed with cardiomyopathy that have experienced one ATE episode, have recovered from the acute syndrome and have no other significant health conditions may be referred by their veterinarian to enter the study. Study participants will receive a supply of either clopidogrel or rivaroxaban free of charge, as well as funds to defray the cost of four follow-up visits with board-certified veterinary cardiologists. Owners will be expected to fill out a 10-minute questionnaire every other month on their cat's health and activity level. In the case of an ATE recurrence, owners can opt to continue or change their cat's anticoagulant treatment.

The study is funded by the Morris Animal Foundation and is being conducted in collaboration with partners at Cornell University, North Carolina State University, Auburn University, Tufts University, Purdue University and Pharmaceutical Specialties Inc.

For more information about the study, visit www.t.uga.edu/24x or the official SUPER-CAT study website, hosted by the Center for Veterinary Critical Care Research, at http://cvccr.com.

 

Filed under: Medical Science, Vet Med

Media Relations

Executive Director for Media Communications
Greg Trevor

706 / 542-8025
Executive Editor for Media Relations
David Bill

706 / 542-9150
Media Relations Coordinator
Sara Freeland

706 / 542-8077
Media Relations Coordinator for Broadcast
Melissa Jackson

706 / 542-8089

Open Records

Open Records Manager
Bob Taylor

706 / 542-8095